$Cerebras Systems(CBRS) Drops -2.23% to $164.17: OpenAI Partner Nears 52-Week Low, $160 Support U...
๐ Market Recap
As of October 10, 2026, 'CBRS' closed at $164.17, down -2.23% (-$3.75) on the day. The stock swung between $162.48 and $170.11, leaving it just 2.1% above its 52-week low of $160.81. With a total market cap of $39.0 billion and a floating market cap of only $4.93 billion, this AI infrastructure name remains highly volatile. The price now sits 57.5% below its 52-week high of $386.34, underscoring a prolonged downtrend fueled by competitive fears and insider selling concerns.
๐ Key Drivers
- OpenAI Partnership Uncertainty: Sam Altman publicly called Cerebras a "close partner", but reports that OpenAI may use Nvidia GPUs for GPT-6.1 Ultrafast mode triggered a nearly 20% weekly plunge last week.
- Insider Selling Pressure: Foundation Capital reduced its stake by over 5 million shares, while CEO Andrew D. Feldman increased his holdings slightly, sending mixed signals to retail investors.
- AI Chip Competition: Investor anxiety over Cerebras' ability to defend its niche against Nvidia's ecosystem continues to overshadow its unique wafer-scale engine advantages.
๐ฏ Price Outlook
Short-Term Upside/Downside Probability
| Direction | Probability | Price Range | Change |
|---|---|---|---|
| Upside | 45% | 170 โ 178 | +3% ~ +8% |
| Downside | 55% | 158 โ 162 | -2% ~ -4% |
Medium-Term Upside/Downside Probability
| Direction | Probability | Price Range | Change |
|---|---|---|---|
| Upside | 52% | 180 โ 200 | +10% ~ +22% |
| Downside | 48% | 140 โ 155 | -6% ~ -15% |
Key Price Range
| Type | Price |
|---|---|
| Short-Term Resistance | 170 / 178 |
| Short-Term Support | 162 / 158 |
| Strong Support Zone | 160.81 (52-Week Low) |
(The above forecasts are generated by AI, for reference only, and do not constitute any form of investment advice, trading guidance, or return commitment)
Below is a technical, valuation, and short-term catalyst analysis based on market data and public information. Views are for exchange only and not direct trading advice.
1. Technical Analysis ๐
Volume: Trading volume reached 6.54 million shares with a volume ratio of 0.62, indicating below-average participation. Total trading value was $1.08 billion, suggesting cautious positioning near the 52-week low rather than panic selling.
MACD: DIF (-7.93) remains below DEA (-5.30), with the histogram at -5.25 and still expanding downward. This confirms persistent bearish momentum with no sign of a bullish crossover yet.
RSI: The 6-day RSI has dropped to 27.48, entering oversold territory, while the 12-day RSI sits at 35.69. The 24-day RSI at 41.76 shows that medium-term weakness is accelerating, though short-term oversold conditions could trigger a technical rebound.
KDJ: The K value (14.14) is well below D (20.29) with J at 1.85, signaling extreme oversold conditions. Historically such compressed readings can precede a sharp mean-reversion bounce.
2. Key Price Levels ๐ฏ
Primary Support: $160.81 (52-week low). A decisive break below this level could trigger capitulation selling toward $150 or lower.
Strong Resistance: $199.84 (recent swing high). Reclaiming this level would require a significant fundamental catalyst and signal a potential trend reversal.
Immediate Pivot: $170.00 (psychological round number and intraday resistance). Bulls must reclaim this level to shift short-term momentum positive.
3. Valuation Perspective ๐ฐ
CBRS trades at a forward P/E of -356.44, slightly better than its historical average of -317.08 but still deeply negative due to ongoing losses. The P/S ratio TTM stands at 57.30, exceptionally high for the semiconductor sector. Price-to-Book is 4.26 and ROE is 18.79%, while ROA remains negative at -5.30%, reflecting the company's heavy reinvestment phase in wafer-scale AI hardware.
4. Analyst Targets ๐ฏ
Eleven institutions cover CBRS with an average target price of $291.64, representing roughly 78% upside from current levels. The median target sits between $209 (low) and $330 (high). Among analysts, 2 rate it Strong Buy, 9 rate it Buy, and 1 rates it Hold. Notably, Morgan Stanley recently raised its price target from $273 to $279 while maintaining an Overweight rating, reflecting conviction in Cerebras' long-term AI infrastructure positioning despite near-term volatility.
5. Weekly Outlook ๐ฎ
Barring a fresh negative headline from the OpenAI/Nvidia narrative, the stock is expected to oscillate between $160 and $175 over the next week. Oversold RSI and KDJ readings suggest a relief bounce is possible, but any recovery will likely face strong supply near the $170 pivot. A decisive break below $160 could accelerate losses toward the $150 psychological floor. Conversely, a close above $178 would open the path to retest $200.
Key events to monitor in the coming 1-2 weeks:
- Any further clarification from OpenAI or Cerebras management regarding GPT-6.1 Ultrafast chip selection.
- Additional insider transaction filings, especially from Foundation Capital or Alpha Wave Global.
- New partnership announcements similar to the Gimlet Labs collaboration to offset competitive concerns.
- Broader AI semiconductor sector sentiment driven by Nvidia earnings and hyperscaler capex guidance.
Risk Disclaimer โ ๏ธ
This article is for informational purposes only and does not constitute investment advice. Stock market investments carry risk, and past performance does not indicate future results. CBRS remains a high-beta, unprofitable AI hardware company with extreme concentration risk tied to a limited number of large customers. Any deterioration in the OpenAI relationship or failure to scale revenue could cause significant additional downside beyond current levels.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

